A5029554856- Psoriasis: Treatment and Pathogenesis
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- melanin and skin pigmentation
- Skin Protection and Aging
- Drug-Induced Adverse Reactions
- Cutaneous Melanoma Detection and Management
- Inflammatory Bowel Disease
- Health Systems, Economic Evaluations, Quality of Life
- Hair Growth and Disorders
- Urticaria and Related Conditions
- Dermatologic Treatments and Research
- Acne and Rosacea Treatments and Effects
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Nonmelanoma Skin Cancer Studies
- Therapeutic Uses of Natural Elements
- Asthma and respiratory diseases
- Pharmacogenetics and Drug Metabolism
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Optical Coherence Tomography Applications
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
University of Siena
2023-2024
Psoriasis is an inflammatory skin disease with a chronic relapsing course and often-detrimental impact on patients' quality of life. Thanks to incredible advances in research over the past few decades, therapeutic armamentarium psoriasis now reasonably broad structured, several agents that have demonstrated successful long-term control this condition. However, there are still unfulfilled gaps resulting from inherent limitations existing therapies, which paved way for identification new...
The risk of developing non-melanoma skin cancers (NMSCs) in patients with psoriasis is highly debated, and, to date, there no unambiguous consensus opinion. Psoriasis known be related an increased likelihood other comorbidities such as psoriatic arthritis, obesity, metabolic syndrome, depression, and cardiovascular disease. Regarding cancer risk, previous studies have reported a greater tendency for the development cutaneous T-lymphomas colon, breast, kidney, lung cancers. Furthermore, data...
Background/Objectives: Psoriasis (PsO) is a chronic inflammatory skin disease that severely impacts patients’ quality of life (QoL). Its global prevalence about 2%, with significant regional variations. PsO manifests in the form erythematous and scaly plaques, causing intense pruritus discomfort limiting daily activities. The condition often includes comorbidities such as psoriatic arthritis, cardiovascular diseases, metabolic syndrome, further deteriorating QoL. Psychological well-being...
Extra facial lentigo maligna (EF-LM) arises outside the head and neck area. EF-LM presents classic histological features of maligna. The dermoscopic aspects have been poorly studied.The primary aims our study were to analyse describe clinical, confocal microscopy a series histologically confirmed EF-LM.We conducted retrospective multicentric study. From database, we selected 48 cases thin melanomas on photodamaged skin with which images available, control group 45 lesions, that can be...
BACKGROUND: Psoriasis (PsO) is a common immune mediated inflammatory disease, affecting about 60 million people worldwide. Although current therapies have dramatically changed the therapeutic approach to heterogeneity of responses often results in an essential unmet clinical need. This study describes design and development Registry (Pso-Reg), Italian electronic-based-registry, aimed collect real life data patients with psoriasis.METHODS: Pso-Reg multicenter, retrospective observational...
The use of biologics in psoriatic patients with a history malignancy is still grey zone the clinical practice. Guidelines recommend that these drugs should be avoided subjects current or recently diagnosed malignancy, unless it has been treated more than 5 years earlier [1]. However, may also considered severe psoriasis and recent diagnosis (i.e., within years) multidisciplinary joint decision oncologists. Still, due to scanty literature on this topic, many clinicians prefer avoiding...